Therefore, understanding these genetic underpinnings is critical for advancing precision medicine approaches in diabetes care, enabling tailored pharmacotherapy and optimising treatment outcomes. By integrating genetic insights into clinical decision-making, this paper highlights the potential of pharmacogenomics not only to identify populations at risk of developing T2DM but also to improve glycaemic control, reduce adverse drug reactions, and enhance patients' quality of life with T2DM.
Ngcobo et al. (Sun,) studied this question.